FUTURE IWG SYMPOSIA

News in the pathogenesis and treatment of glomerular disease
IWG (Immunonephrology Working Group)
IWG

Part I - Complement mediated diseases: pathogenesis, new entities, upcoming treatments, how to handle expensive drugs
Complement activation in immune-mediated glomerular disease
Mohamed R. Daha, Leiden, The Netherlands
Complement staining in kidney biopsy (C3, C4, C5b-9)
Pablo Cannata-Ortiz, Madrid, Spain
Complement in ANCA-associated Vasculitis - new therapeutic target?
Annette Bruchfeld, Stockholm, Sweden
Complement activation in IgA nephropathy, membranous nephropathy and FSGS
Yasar Caliskan, Istanbul, Turkey
Targeting complement in atypical hemolytic uremic syndrome and C3 glomerulopathy
Giuseppe Remuzzi, Bergamo, Italy

Part II - Individualized (personalized) treatment of glomerular disease – is it already possible?
Personalized immunomonitoring and treatment in lupus nephritis
Hans-Joachim Anders, Munich, Germany
Personalized monitoring and treatment in membranous nephropathy
Jack F.M. Wetzels, Nijmegen, The Netherlands
Personalized approach to IgA nephropathy, is supportive care the response for most patients?
Renato Monteiro, Paris, France
Personalized treatment in ANCA-associated vasculitis
Mårten Segelmark, Linköping, Sweden
Hematuria in glomerular disease - is it important for the outcome of the patients?
Jesus Egido, Madrid, Spain

- See more at: http://www.era-edta2017.org/en-US/preliminary-scientific-programme-1#sthash.S273ZyBf.dpuf
News in the pathogenesis and treatment of glomerular disease
IWG (Immunonephrology Working Group)
IWG

Part I - Complement mediated diseases: pathogenesis, new entities, upcoming treatments, how to handle expensive drugs
Complement activation in immune-mediated glomerular disease
Mohamed R. Daha, Leiden, The Netherlands
Complement staining in kidney biopsy (C3, C4, C5b-9)
Pablo Cannata-Ortiz, Madrid, Spain
Complement in ANCA-associated Vasculitis - new therapeutic target?
Annette Bruchfeld, Stockholm, Sweden
Complement activation in IgA nephropathy, membranous nephropathy and FSGS
Yasar Caliskan, Istanbul, Turkey
Targeting complement in atypical hemolytic uremic syndrome and C3 glomerulopathy
Giuseppe Remuzzi, Bergamo, Italy

Part II - Individualized (personalized) treatment of glomerular disease – is it already possible?
Personalized immunomonitoring and treatment in lupus nephritis
Hans-Joachim Anders, Munich, Germany
Personalized monitoring and treatment in membranous nephropathy
Jack F.M. Wetzels, Nijmegen, The Netherlands
Personalized approach to IgA nephropathy, is supportive care the response for most patients?
Renato Monteiro, Paris, France
Personalized treatment in ANCA-associated vasculitis
Mårten Segelmark, Linköping, Sweden
Hematuria in glomerular disease - is it important for the outcome of the patients?
Jesus Egido, Madrid, Spain

- See more at: http://www.era-edta2017.org/en-US/preliminary-scientific-programme-1#sthash.S273ZyBf.dpuf
News in the pathogenesis and treatment of glomerular disease
IWG (Immunonephrology Working Group)
IWG

Part I - Complement mediated diseases: pathogenesis, new entities, upcoming treatments, how to handle expensive drugs
Complement activation in immune-mediated glomerular disease
Mohamed R. Daha, Leiden, The Netherlands
Complement staining in kidney biopsy (C3, C4, C5b-9)
Pablo Cannata-Ortiz, Madrid, Spain
Complement in ANCA-associated Vasculitis - new therapeutic target?
Annette Bruchfeld, Stockholm, Sweden
Complement activation in IgA nephropathy, membranous nephropathy and FSGS
Yasar Caliskan, Istanbul, Turkey
Targeting complement in atypical hemolytic uremic syndrome and C3 glomerulopathy
Giuseppe Remuzzi, Bergamo, Italy

Part II - Individualized (personalized) treatment of glomerular disease – is it already possible?
Personalized immunomonitoring and treatment in lupus nephritis
Hans-Joachim Anders, Munich, Germany
Personalized monitoring and treatment in membranous nephropathy
Jack F.M. Wetzels, Nijmegen, The Netherlands
Personalized approach to IgA nephropathy, is supportive care the response for most patients?
Renato Monteiro, Paris, France
Personalized treatment in ANCA-associated vasculitis
Mårten Segelmark, Linköping, Sweden
Hematuria in glomerular disease - is it important for the outcome of the patients?
Jesus Egido, Madrid, Spain

- See more at: http://www.era-edta2017.org/en-US/preliminary-scientific-programme-1#sthash.S273ZyBf.dpuf

SEID (Scientific and Educational Interaction Day)

Starting from 2019 ERA-EDTA has decided to create a special Scientific and Educational Interaction Day to encourage ERA-EDTA working groups to develop joint project proposals by forming alliances, fostering international collaborations and integrating different (sub-) specialties.

The first SEID will be held in Vienna, Austria on October 26, 2019.

Click here to open the SEID annoucement.